Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early ...

Issuer: Mainz Biomed N.V. / Key word (s): Miscellaneous Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month 11.02.2025 / 14:01 ...

The launch coincides with March Colorectal Cancer Awareness Month, a global initiative emphasizing the importance of early ...

Boliden AB (LEI code: 21380059QU7IM1ONDJ56) has during February 7 and 10, 2025, repurchased a total of 100,000 treasury shares (ISIN code: SE0020050417) as part of the repurchases resolved by the ...

U.S. Sen. Susan Collins said she also opposes "the poorly conceived conceived directive" from the National Institutes for ...

Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

Cambridge, Massachusetts Thursday, February 6, 2025, 13:00 Hrs [IST] ...

Over the summer, two graduate students attended a highly sought-after training program at Cold Spring Harbor Laboratory (CSHL ...

Avison Young, a leading global real estate services firm, is set to transform its real estate operations in the United Arab ...